Investigational drug for treating metastatic pancreatic cancer

Trial ID:
IRB-22-8008
Darren Sigal, M.D.
This phase II study will test the safety and anti-tumor activity of an investigational anti-Leukemia Inhibitory Factor (Anti-LIF) drug called AZD0171, in combination with FDA approved standard of care Durvalumab and Chemotherapy for the treatment of locally advanced or metastatic pancreatic adenocarcinoma.
*Have pathologically diagnosed locally advanced or metastatic pancreatic adenocarcinoma (mPDAC)<br>*Be willing to submit an archived or fresh tumor specimen for central testing<br>*Have normal organ function<br>*Be over the age of 18 years old

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org